The first drug prices targeted include Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and versions of Fiasp.
Author: Ken Alltucker, USA TODAY
Medicare’s priciest drugs may get cheaper as feds start negotiations. Big Pharma objects.
For the first time, the federal government is allowed to negotiate drug prices for older Americans. Medicare will name the first 10 drugs by Friday.
Gender-affirming surgeries nearly triple as states enact restrictions
Patients getting gender-affirming operations nearly tripled in recent years. States are limiting these surgeries for minors, though few have them.
Dengue fever in Florida on the rise. As virus cases grow, here’s how to spot symptoms
Dengue, spread through mosquito bites, has been found in Florida’s Miami-Dade and Broward counties.
Amazon Pharmacy offers insulin discounts amid price hikes: ‘Making it as simple as possible’
Amazon Pharmacy will apply manufacturer coupons to more than 14 commonly-used insulin products to ease consumer purchases.
Popular heartburn medicine increases dementia risk by 33%. What to know to stay safe.
People who took acid reflux drugs for more than 4 years faced a 33% greater likelihood of developing dementia
Nearly half of Americans interested in weight-loss drugs like Wegovy, survey finds
A KFF health tracking poll found 45% of people are interested in taking a safe and effective weight loss medication
Henrietta Lacks’ family settles lawsuit over use of HeLa cells to advance medical research
The lawsuit demanded the family be paid for the company’s use of Henrietta Lacks’ cells, which were taken without consent in the 1950s and used in research.
Young and middle-aged adults with depression face greater dementia risk later in life
The study of 1.4 million Danish adults found those with depression in early- and middle age were twice as likely to get dementia later in life.
Eli Lilly’s donanemab slows early stages of Alzheimer’s disease, study shows
The data published Monday in the Journal of the American Medical Association found the drug donanemab slowed decline by 35% compared to placebo.